SEARCH:   Advanced

Blood, 1 August 2007, Vol. 110, No. 3, pp. 902-907. Prepublished online as a Blood First Edition Paper on April 13, 2007; DOI 10.1182/blood-2007-01-066837. This Article Abstract Full Text (PDF) All Versions of this Article: blood-2007-01-066837v1 110/3/902    most recent Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Rights and Permissions Citing Articles Citing Articles via HighWire Citing Articles via CrossRef Citing Articles via Google Scholar Google Scholar Articles by Standeven, K. F. Articles by Ariëns, R. A. S. Search for Related Content PubMed PubMed Citation Articles by Standeven, K. F. Articles by Ariëns, R. A. S. Related Collections Hemostasis, Thrombosis, and Vascular Biology Social Bookmarking                   What's this?  Previous Article  |  Table of Contents  |  Next Article  HEMOSTASIS, THROMBOSIS, AND VASCULAR BIOLOGY Functional analysis of fibrin -chain cross-linking by activated factor XIII: determination of a cross-linking pattern that maximizes clot stiffness Kristina F. Standeven1, Angela M. Carter1, Peter J. Grant1, John W. Weisel2, Irina Chernysh2, Leona Masova2, Susan T. Lord3, and Robert A. S. Ariëns1 1 Academic Unit of Molecular Vascular Medicine, Leeds Institute for Genetics Health and Therapeutics, Faculty of Medicine and Health, University of Leeds, Leeds, United Kingdom; 2 Department of Cell and Developmental Biology, University of Pennsylvania School of Medicine, Philadelphia; 3 Department of Pathology and Laboratory Medicine, University of North Carolina, Chapel Hill    Abstract Top Abstract Introduction Materials and methods Results Discussion Authorship References   Activated coagulation factor XIII (FXIIIa) cross-links the -chains of fibrin early in clot formation. Cross-linking of the -chains occurs more slowly, leading to high molecular weight multimer formations that can also contain -chains. To study the contribution of FXIIIa-induced -chain cross-linking on fibrin structure and function, we created 2 recombinant fibrinogens (Q398N/Q399N/K406R and K406R) that modify the -chain cross-linking process. In K406R, -dimer cross-links were absent, but FXIIIa produced a cross-linking pattern similar to that observed in tissue transglutaminase cross-linked fibrin(ogen) with mainly - cross-links. In Q398N/Q399N/K406R, cross-links with any -chain involvement were completely absent, and only -chain cross-linking occurred. Upon cross-linking, recombinant normal fibrin yielded a 3.5-fold increase in stiffness, compared with a 2.5-fold increase by -chain cross-linking alone (Q398N/Q399N/K406R). K406R fibrin showed a 1.5-fold increase in stiffness after cross-linking. No major differences in clot morphology, polymerization, and lysis rates were observed, although fiber diameter was slightly lower in cross-linked normal fibrin relative to the variants. Our results show that -chain cross-linking contributes significantly to clot stiffness, in particular through -dimer formation; - hybrid cross-links had the smallest impact on clot stiffness.    Introduction Top Abstract Introduction Materials and methods Results Discussion Authorship References   After cross-linking by FXIIIa, fibrin becomes markedly more resistant to proteolytic and mechanical disruption. The introduction of N-(-glutamyl)lysine isopeptide bonds between fibrin molecules within and between clot fibers has a remarkable effect on the rheologic properties of clots.1–4 This stabilization of fibrin fibers leads to the formation of a rigid and elastic structure that is capable of stopping leakages in the circulatory system, whereas bleeding is a frequent problem without FXIIIa cross-linking. Of the 3 fibrinogen chains, only the - and -chains, but not the ß-chains, become cross-linked by FXIIIa. During clot formation, at the early stages of polymerization, cross-linking occurs within emerging protofibrils between K406 and Q398 and/or Q399, resulting in the formation of -dimers.5–7 Multiple cross-linking between fibrin -chains results in the formation of -polymers.6 Over time, FXIIIa has been shown to generate cross-linked chain structures containing various combinations of - and/or -chains; mainly these are thought to be n,8 but 3, 4, and hybrid pq (n, p, and q = 1, 2, 3, respectively, and so forth) are also known to occur.9,10 The effect of these different cross-linking formations on fibrin clot function has not been fully clarified. Previously, the increase of stiffness in clots has been attributed to -chain cross-linking.11 On the other hand, a recent study suggested that -chain cross-linking played a major role in the determination of the viscoelastic properties of fibrin.12 However, in these studies, chain-specific cross-linking was manipulated either by antibodies or by the use of truncated molecules, with inherent difficulties in interpretation arising from the effects of these modifications themselves on fibrin structure and function. We chose a different approach by creating full-length fibrinogen variants with substitutions in the FXIII cross-linking sites on the fibrinogen -chain to enable us to study the contribution of -chain cross-linking to fibrin structure and function. In the experiments reported here, we examined the structural and physical properties of clots using these variants with modified -chain cross-linking    Materials and methods Top Abstract Introduction Materials and methods Results Discussion Authorship References   Vector construction and expression of recombinant fibrinogens The expression vector pMLP-, which contains the entire fibrinogen -chain cDNA, has been described elsewhere.13 To create K406R, codon 406 was altered from AAA (lysine) to CGA (arginine) using the QuickChange site-directed mutagenesis kit (Stratagene, La Jolla, CA). The following primers (Invitrogen, Poole, United Kingdom) were used: 5'-CACCACCTGGGGGGAGCCCGACAGGCTGGAGACGTTTAAAAG-3' and 5'-CTTTTAAACGTCTCCAGCCTGTCGGGCTCCCCCCAGGTGGTG-3' (mutated codon in bold). The resulting vector was used as a template to create Q398N/Q399N/K406R with the following primers: 5'-CTCACAATTGGAGAAGGAAACAACCACCACCTGGGGGG-3' and 5'-CCCCCCAGGTGGTGGTTGTTTCCTTCTCCAATTGTGA-3' (mutated codons in bold). Mutations were confirmed by sequencing using an ABI PRISM312 automated sequencer (Applied Biosystems, Warrington, United Kingdom). Chinese hamster ovary cells expressing the human A and Bß fibrinogen chains were cotransfected with the variant -chain vectors and a plasmid containing a selection gene, pMSV his.13 Normal and variant fibrinogen were expressed and purified as previously described.14 Purified proteins were dialyzed against 100 mmol l–1 NaCl, 50 mmol l–1 Tris, pH 7.4, and stored at –80°C. The same buffer was used throughout the entire study for the formation of fibrin clots. Purity of preparations was analyzed by sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) under reducing and nonreducing conditions following the method of Laemmli.15 Preparation of FXIII A plasma-derived concentrate of FXIII, used clinically for the treatment of patients with FXIII deficiency (fibrogammin P; ZLBBehring, Sussex, United Kingdom), was separated from contaminating albumin and glucose using gel filtration. In brief, 250 U fibrogammin dissolved in 20 mmol l–1 Hepes, pH 7.4, was separated on Sepharose 6B (2.6 x 38-cm column) using a BioCad Sprint Chromatography system (Applied Biosystems), with 20 mmol l–1 Hepes, pH 7.4, and a flow rate of 0.5 mL min–1. Fractions containing FXIII A2B2 tetramers were concentrated by centrifugation using Amicon Centriplus YM-100 centrifugal devices (Millipore, Billerica, MA), dialyzed against 100 mmol l–1 NaCl, 50 mmol l–1 Tris, pH 7.4, and stored at –80°C. The FXIII obtained by this procedure was pure as determined by SDS-PAGE and of similar activity as plasma-purified FXIII used in our previous studies.16 Cross-linking of fibrin by FXIIIa Fibrinogen (0.4 mg mL–1 final concentration) and 0.022 mg mL–1 FXIII in 100 mmol l–1 NaCl, 50 mmol l–1 Tris, pH 7.4, were incubated with 0.25 U mL–1 human -thrombin (Calbiochem, Darmstadt, Germany) and 5 mmol l–1 CaCl2 for 0, 5,10, 30, 60, and 180 minutes at 37°C. The reaction was stopped by the addition of reducing sample buffer (Invitrogen) and heating the samples for 5 minutes at 85°C. Samples were separated on a 3% to 8% Tris-acetate gradient gel (Invitrogen). Proteins were visualized on the gels using GelCode blue stain reagent (Pierce, Rockport, IL). Cross-linking of fibrin by guinea pig liver transglutaminase Fibrinogen (0.4 mg mL–1) was cross-linked upon addition of 1 U mL–1 guinea pig tissue liver transglutaminase (tTG; Sigma) and 10 mmol l–1 CaCl2 and 0.25 U mL–1 human -thrombin. Samples were incubated at 37°C for 180 minutes and processed as described under "Cross-linking of fibrin by FXIIIa." Identification of cross-linking products The composition of cross-linking products was determined by immunoblotting and matrix-assisted laser desorption/ionization mass spectrometry (MALDI-MS). Samples were incubated at 37°C for one hour, separated by SDS-PAGE as described above, and transferred to a nitrocellulose membrane (Pierce). To distinguish between - and -chain formations, 2 murine monoclonal antibodies were used, directed against residues 15-35 in the -chain and 290-348/349-406 in the -chain (both from Accurate Chemical & Scientific, Westbury, NJ); a peroxidase-conjugated secondary antibody was used for detection with tetramethyl benzidine (Calbiochem). All bands of interest were excised from the gel after SDS-PAGE, digested with trypsin, and analyzed by MALDI-MS. Viscoelastic properties of fibrin clots Clots were prepared between 2 12-mm-diameter glass coverslips that were positioned 1 mm apart in a torsion pendulum as previously described.17 Recombinant fibrinogen variants and plasma purified fibrinogen (Calbiochem; further purified by IF-1 affinity chromatography18) were incubated at 0.75 mg mL–1 with 10 mmol l–1 CaCl2 and 1 U mL–1 human -thrombin, with or without 0.022 mg mL–1 FXIII. Sixty minutes after initiation of clotting, a momentary impulse was applied to one arm of the torsion pendulum by air pressure, which caused free oscillations of the arm with strains of less than 3%. The oscillations were recorded on a chart recorder and used to calculate the storage modulus, G', in dyne cm–2, which reflects the stiffness of the fibrin clot.17 Polymerization of fibrinogen and macroscopic fibrinolysis velocity by turbidity Polymerization of normal and variant recombinant fibrinogens (final concentration 0.33 mg mL–1) was measured in a microtiter plate turbidity assay as previously described.12 Samples were incubated with 0.25 U mL–1 thrombin and 5 mmol l–1 calcium chloride in 100 mmol l–1 NaCl, 50 mmol l–1 Tris, pH 7.4, in the presence and absence of 0.022 mg mL–1 FXIII. Increase of turbidity was continually monitored every 12 seconds on a FLX-800 multiwell plate reader (Biotek, Instruments, Winooski, VT) over a period of 60 minutes at ambient temperature. After completion of polymerization at 60 minutes, all wells were overlaid with 100 µL of a mixture of 10 nmol l–1 tissue plasminogen activator (Technoclone, Vienna, Austria) and 0.05 mg mL–1 Glu-plasminogen (Calbiochem). Changes in turbidity were monitored every 12 seconds for 60 minutes, as above. After completion of lysis, cross-linked samples were reduced by the addition of SDS sample buffer and analyzed on a 3% to 8% gradient gel. Scanning electron microscopy Normal and variant fibrinogens at 0.4 mg mL–1 were incubated with 0.25 U mL–1 human -thrombin and 5 mmol l–1 CaCl2, with or without 0.022 mg mL–1 FXIII. Clots were prepared for microscopy as described previously.17 Samples were observed and photographed digitally using a Field Emission Scanning Electron Microscope (LEO1530 FEGSEM; Leo Electron Microscopy, Cambridge, United Kingdom) at a magnification of 10 000 x. Average fiber diameters of 200 fibers were measured from 5 pictures per clot by an operator blind to variant type using ImageJ 1.29x software (National Institutes of Health, Bethesda, MD). Statistical analysis Data were described as mean and standard deviation. Distribution of fiber diameters was normal as tested according to Kolmogorov-Smirnov. Differences in fiber diameters were investigated by analysis of variance (ANOVA) with posthoc Bonferroni analysis. All statistical analyses were performed using SPSS for Windows version 12 software (SPSS, Chicago, IL). P values lower than .05 were considered to indicate statistical significance.    Results Top Abstract Introduction Materials and methods Results Discussion Authorship References   Cross-linking of fibrin by FXIIIa A time course of cross-linking of variant and normal fibrin by FXIIIa, resolved on a 3-8% Tris-acetate SDS-PAGE, is shown in Figure 1. After 5 minutes of cross-linking, a strong band representing -dimer formation was observed in normal fibrin (Figure 1 lane 1), which was absent from both Q398N/Q399N/K406R (lane 2) and K406R (lane 3) variants. With normal fibrin, the band for -chain monomer was virtually absent after 5 minutes. There was also a visible decrease of the -band when compared with the ß-band, which, due to a lack in cross-linking sites, retained the same intensity throughout the entire time course. In K406R, a visible proportion of the -chain was cross-linked after 5 minutes, and there was a noticeable decrease in the -chain band (Figure 1). Five distinct higher molecular weight bands were visible at 5 minutes, at least 3 of which (marked with * in Figure 1) appeared only in K406R and not in the other variant or in normal cross-linked fibrin. A reduced rate of -chain consumption during initial time points, and no involvement of the -chains over 180 minutes, occurred in Q398N/Q399N/K406R (Figure 1). The cross-linking pattern of all variants changed over the first 30 minutes, with a reduction and disappearance of some bands, due to incorporation of these cross-linking species in higher molecular weight complexes that accumulated on top of the loading wells. -Chain cross-linking appeared complete after 30 minutes in normal and K406 and after 60 minutes in Q398N/Q399N/K406R (Figure 1). -Chain cross-linking in normal fibrin was complete after 5-minute incubation, whereas cross-linking of the -chains in K406R did not proceed to completion during the 3-hour incubation period, despite the early reduction in -monomer band intensity of this variant. There was no reduction of the -monomer band over 180 minutes in Q398N/Q399N/K406R (Figure 1). View larger version (59K): [in this window] [in a new window]   Figure 1. Cross-linking of fibrin variants by FXIIIa. Lane 1 of each panel: recombinant normal fibrin; lane 2: Q398N/Q399N/K406R; lane 3: K406R. Roman numerals in the 60-minute time point denote origin of cross-link formations as identified by MALDI-MS and Western blotting with chain-specific antibodies; I: -dimers, II: - hybrid formation, III: - cross-links. After 5 minutes, nearly all -chains and a large proportion of the -chain were cross-linked in normal fibrinogen. In K406R, FXIIIa preferentially cross-linked the -chain; after 180 minutes, a substantial amount of -chain remained. No -chain cross-linking occurred in Q398N/Q399N/K406R. In all fibrinogens, early, relatively lower molecular weight, cross-linking bands disappeared over time, as these transient oligomers become incorporated into larger-molecular-weight molecular complexes that do not enter the gel.   Identification of FXIIIa cross-linking products by immunoblotting and MALDI-MS Immunoblotting with chain-specific antibodies and MALDI-MS analysis was used to identify the fibrin chains in the cross-linked products at 60 minutes (data not shown); the fibrinogen chains from which bands originated are designated by roman numerals in Figure 1. It was found that all high molecular weight formations in K406R contained both - and -chains, therefore representing - cross-links. No distinct bands for - cross-linking products could be detected in K406R, although the existence of homogenous - multimers that were prevented from entering the gel cannot be excluded. In normal fibrin, as expected, the -dimer band contained only -chains (Figure 1). The cross-linking products in Q398N/Q399N/K406R did not react with the anti- antibody and no -chain signal was detected by MALDI-MS. Cross-linking of fibrinogen and fibrin by tTG Both human red cell and guinea pig liver tTG have been shown to preferentially produce - cross-link formations, at the expense of dimeric -chain cross-linking.19,20 It was of interest to detect whether in the absence of K406, FXIIIa would alter its cross-linking pattern of the fibrinogen -chain that is normally centered around -dimer band, leading to cross-linking products similar to those induced by tTG. Indeed, tTG-cross-linked normal fibrin contained products very similar to FXIIIa-cross-linked K406R, with the exception of a small amount of -dimer present in the tTG-cross-linked normal fibrin sample, which was absent in either FXIIIa- or tTG-cross-linked K406R (Figure 2). In Q398N/Q399N/K406R fibrin clots, tTG readily cross-linked the -chains to each other, but found no available residues for cross-linking on the -chains. In tTG-cross-linked fibrinogen samples, similar patterns were found as those observed in fibrin clots, but cross-linking occurred as expected at a slower rate, and there was no -dimer present in normal fibrin (data not shown). Generally, tTG preferentially cross-linked the -chains rather than the -chains in all samples (Figure 2B). All tTG-cross-linked samples showed 2 bands of a molecular weight between 102 000 and 122 000 kDa, which were caused by impurities in the commercial tTG preparation, as they were not evident in blots with fibrinogen-specific antibodies, but were present on SDS-PAGE of tTG alone (data not shown). View larger version (76K): [in this window] [in a new window]   Figure 2. Cross-linking of fibrinogen and fibrin by tTG. Comparison of FXIIIa (A) and guinea pig tTG-cross-linked products (B). Lanes 1 and 4: normal recombinant fibrin; lanes 2 and 5: Q398N/Q399N/K406R; lanes 3 and 6: K406R. Bands are labeled as in Figure 1. With the exception of a faint -dimer band, the cross-linking pattern in tTG-cross-linked normal recombinant fibrin is similar to that of FXIIIa- and tTG-cross-linked K406R. Nature of the cross-linking bands was identified by Western blotting.   Stiffness of clots made from the fibrinogen variants The storage modulus G', which is as a measure of clot rigidity, was comparable for all samples before addition of FXIII (Table 1). After cross-linking by FXIIIa, clots made from the fibrinogen -chain variants markedly differed in stiffness. Cross-linking by FXIIIa increased stiffness of clots in all samples, but to a different extent: normal samples demonstrated the most drastic increase in stiffness, with G' increasing 3.5-fold (Table 1). In clots made from the Q398N/Q399N/K406R fibrinogen variant, where cross-linking of the -chain is completely abolished as shown above, G' increased 2.5-fold, indicating that cross-linking of the -chain alone is not solely responsible for clot stiffness, and that -dimer and -multimer formation must play a role. The smallest increase (1.5-fold) induced by FXIIIa cross-linking was achieved in K406R clots (Table 1), indicating that - cross-links are least effective in enhancing clot rigidity. View this table: [in this window] [in a new window]   Table 1. Fibrin clot stiffness with and without cross-linking   Macroscopic and microscopic evaluation of fibrin clot morphology No striking differences could be detected in the overall morphologic appearance of the clots before and after cross-linking, using macroscopic (turbidity) techniques and microscopic (scanning electron microscopy). Macroscopic analyses did not reveal significant differences in fibrin polymerization rate, rate of protofibril formation, or clot morphology (data not shown). In contrast, microscopic measurements of non–cross-linked fibers revealed that, while there was no difference between normal and K406R clots, Q398N/Q399N/K406R fibers were characterized by a slightly larger fiber diameter (Table 2). Fiber diameter in normal fibrin decreased subtly with cross-linking, in accordance with previous reports in the literature.21 In both K406R and Q398N/Q399N/K406R samples, cross-linking led to an increase in fiber diameter (Table 2). View this table: [in this window] [in a new window]   Table 2. Fiber diameter with and without FXIIIa cross-linking (determined by scanning electron microscopy)   Fibrin clot lysis We investigated rates of fibrinolysis by following loss of turbidity following overlay of fibrin clots with a mixture of tissue plasminogen activator and plasminogen. Using the methods and conditions used, we did not observe differences in lysis rates between normal and variant fibrins, or between cross-linked and non–cross-linked samples. Subsequent analysis of the lysed samples on SDS-PAGE indicated complete lysis of the very high molecular weight multimers in all variants, although the pattern and composition of lysis products differed significantly for the cross-linked normal and K406R and Q398N/Q399N/K406R variants (data not shown).    Discussion Top Abstract Introduction Materials and methods Results Discussion Authorship References   Previous studies that examined the role of -chain cross-linking in fibrin clot function in the absence of -chain cross-linking made use of molecules with truncated -chains (with all -chain cross-linking residues removed)12 or patient IgG that inhibited formation of high molecular weight cross-linking products while leaving -dimer formation intact (in combination with total FXIII inhibition).11 Here we have taken the opposite and complementary approach, by specifically removing through site-directed mutagenesis the -chain residues involved in the transglutaminase reaction. Using these variants, we were able for the first time to directly characterize the effects of -chain cross-linking on fibrin function, without potential interference of an additional element such as an antibody, or deletion of substantial parts of the molecule. We have found that substitution of the only lysine residue (K406R) involved in the cross-linking process eliminated the production of -dimers due to cross-linking of K406 to Q399 or Q398. However, we also found that FXIIIa produced a number of - hybrid cross-links in this variant by cross-linking the 2 acceptor sites Q398 and/or Q399 to lysine residues in the -chain. Murthy et al20 found that in fibrinogen that was cross-linked with red cell transglutaminase, Q398 and Q399 were cross-linked to AK413 and K418, allowing for 4 possible conformations in hybrid - cross-links: AK413-Q398, AK413-Q399, AK418-Q398, and AK418-Q399. When we cross-linked K406R with FXIIIa or tTG, similar high molecular weight products could be observed, whereas in normal fibrin the cross-linking pattern was clearly different between FXIIIa and tTG. These findings suggest that in K406R fibrinogen, FXIIIa uses the same combination of Q398/399 and AK413/418 as tTG, leading to preferential cross-linking of the - to the -chain of fibrin. FXIII and tTG likely have different in vivo roles, which may require different cross-linking patterns. FXIII is important during the initial stage of clot formation, which requires a fibrin network that is able to seal the circulation at a site of injury, and withstand high pressure from the circulating blood. The role of tTG-cross-linked fibrinogen is not yet fully understood. tTG-cross-linked fibrinogen has been found in the fibrous cap of atherosclerotic lesions, a process that may not require the same physical properties as the creation of a hemostatic plug.22 We have also shown that FXIIIa-dependent -chain cross-linking contributes significantly to clot stiffness, in particular through -dimer formation, which maximizes clot stiffness. Collet et al12 measured stiffness in clots formed from fibrinogen with a truncation at A chain residue 251, a variant without the C-terminal flexible C region, where the -chain FXIII-cross-linking sites are located, hence only allowing for -chain cross-linking. Fibrin clots formed with this variant showed a 1.5 x increase in clot stiffness after FXIII cross-linking compared with a 2.5 x increase in normal fibrin samples. Using our modified fibrinogen molecules, we found a pronounced difference in stiffness between our recombinant normal samples (3.5 x increase) and the K406R variant (1.5 x increase), indicating a major contribution of -chain cross-linking in determining viscoelastic properties of clots. Some of the differences between the results of Collet et al and our current results may be caused by effects of the absence of the C regions in their study, which may contribute to changes in lateral aggregation, fibrin structure, and hence stiffness of the clot. We were able to demonstrate that - cross-linking is a prerequisite for the production of high molecular weight formations that maximally enhance clot stiffness, confirming the hypothesis of Ryan et al11 that the ligation of -chains is likely to provide a structural framework for the later-developing higher-order ligated chain species to enhance network stiffness.11 Interestingly, when we eliminated all -chain cross-linking sites (Q398N/Q399N/K406R), the increase in stiffness induced by cross-linking (2.5 x) was indeed less when compared with recombinant normal fibrinogen (3.5 x), but more than that observed in K406R (1.5 x). As the main difference between the Q398N/Q399N/K406R and the K406R variants is the formation of - hybrid cross-links in the latter, these data suggest that - cross-links are least effective in increasing the stiffness of the clot. We therefore conclude that the observed increase in stiffness following -dimer formation in normal fibrin clots must be due to formation of -multimers and n-polymers, rather than pq-hybrid cross-links. Our data further understanding of the basic mechanisms involved in determining the mechanical properties of fibrin, although further studies are required to elucidate the processes determining the mechanical properties of plasma clots and thrombi.23 The importance of this is highlighted by evidence from epidemiologic studies demonstrating a relationship between cardiovascular events and clot mechanical properties.24,25 Furthermore, the striking effects of - and -chain cross-linking on the decrease of the irreversible changes that occur after the release of stress,26 as well as the extent of increase in the fibrin period on stretching,27 have yet to be explored with these mutants. In addition to viscoelastic properties, we also measured the influence of cross-linking patterns (-, -, and -) on fibrin structure and fibrinolysis. We found the contribution of cross-linking patterns to clot morphology was modest, and we did not find any change in fibrinolysis rates between variants. The relationship between cross-linking and fibrinolysis has been the focus of many studies with conflicting interpretation regarding the contribution of -chain or -chain multimerization or cross-linking per se on fibrinolysis rates.28–30 Using our recombinant variants and the turbidity plate assay, we observed that during early cross-linking (> 60 minutes), FXIII cross-linking did not increase fibrinolysis time. While we appreciate that this reaction time is relatively short to investigate the effects of complete cross-linking on fibrinolysis rates, our data in principle support findings by Siebenlist and Mosesson that there was no directly measurable relationship of resistance to fibrinolysis and the degree of -chain cross-linking, and the formation of -dimers as they occur early on in clot formation did not extend fibrinolysis time.9 We conclude that -dimer formation is essential to generate a pattern of cross-linking by FXIIIa that maximally enhances rigidity in fibrin clots. Formation of - hybrid cross-links, similar to those generated by tTG, is least efficient in strengthening the fibrin fibers. Different cross-linking patterns between the - and -chains and the sequence in which they are formed play a major role in determining clot stiffness.    Authorship Top Abstract Introduction Materials and methods Results Discussion Authorship References   Contribution: K.F.S., A.M.C., P.J.G., and R.A.S.A. devised and managed the project; K.F.S. carried out the experimental procedures (apart from measurements of viscoelastic properties) and wrote the paper; J.W.W., I.C., and L.M. carried out measurements of viscoelastic properties; S.T.L. provided constructs and training on recombinant fibrinogen expression. All authors carried out editorial modifications and read and approved the final version of the paper. Conflict-of-interest disclosure: The authors declare no competing financial interests. Correspondence: Peter J. Grant, Academic Unit of Molecular Vascular Medicine, Leeds Institute for Genetics, Health and Therapeutics, Clarendon Way, University of Leeds, Leeds LS2 9JT UK; e-mail: p.j.grant{at}leeds.ac.uk.    Acknowledgments   The authors wish to thank the British Heart Foundation for their generous support for these studies (PG/02/124/14 502), as well as the National Institutes of Health (HL30954 to J.W.W. and HL31048 to S.T.L.). The authors also would like to thank Mrs Li Fang Ping, Dr Susan Wilhelm, and Dr Bettina Bolliger-Stucki for their excellent advice in the production of recombinant fibrinogen.    Footnotes   Submitted January 12, 2007; accepted April 12, 2007. Prepublished online as Blood First Edition Paper, April 13, 2007 DOI: 10.1182/blood-2007-01-066837 The publication costs of this article were defrayed in part by page charge payment. Therefore, and solely to indicate this fact, this article is hereby marked "advertisement" in accordance with 18 USC section 1734.    References Top Abstract Introduction Materials and methods Results Discussion Authorship References   Ferry JD, Miller M, Shulman S. The conversion of fibrinogen to fibrin, VII: rigidity and stress relaxation of fibrin clots, eff. of calcium. Arch Biochem 1951; 34:424–436.[CrossRef][Medline] [Order article via Infotrieve] Ferry JD. Structure and rheology of fibrin networks. In Kramer O (Ed.). Biological and Synthetic Polymer Networks2007;Amsterdam, the Netherlands Elsevier pp. 41–55. Roberts WW, Lorand L, Mockros LF. Viscoelastic properties of fibrin clots. Biorheology 1973; 10:29–42.[Medline] [Order article via Infotrieve] Mockros LF, Roberts WW, Lorand L. Viscoelastic properties of ligation-inhibited fibrin clots. Biophys Chem 1974; 2:164–169.[CrossRef][Medline] [Order article via Infotrieve] Chen R and Doolittle RF. Identification of the polypeptide chains involved in the cross-linking of fibrin. Proc Natl Acad Sci U S A 1969; 63:420–427.[Abstract/Free Full Text] McKee PA, Mattock P, Hill RL. Subunit structure of human fibrinogen, soluble fibrin, and cross-linked insoluble fibrin. Proc Natl Acad Sci U S A 1970; 66:738–744.[Abstract/Free Full Text] Chen R and Doolittle RF. gamma/gamma-cross-linking sites in human and bovine fibrin. Biochemistry 1971; 10:4487–4491.[Medline] [Order article via Infotrieve] McKee PA, Schwartz ML, Pizzo SV, Hill RL. Cross-linking of fibrin by fibrin-stabilizing factor. Ann N Y Acad Sci 1972; 202:127–148.[Medline] [Order article via Infotrieve] Siebenlist KR and Mosesson MW. Progressive cross-linking of fibrin gamma chains increases resistance to fibrinolysis. J Biol Chem 1994; 269:28414–28419.[Abstract/Free Full Text] Siebenlist KR and Mosesson MW. Evidence of intramolecular cross-linked A alpha. gamma chain heterodimers in plasma fibrinogen. Biochemistry 1996; 35:5817–5821.[CrossRef][Medline] [Order article via Infotrieve] Ryan EA, Mockros LF, Stern AM, Lorand L. Influence of a natural and a synthetic inhibitor of factor XIIIa on fibrin clot rheology. Biophys J 1999; 77:2827–2836.[Medline] [Order article via Infotrieve] Collet JP, Moen JL, Veklich YI, et al. The {alpha}C domains of fibrinogen affect the structure of the fibrin clot, its physical properties, and its susceptibility to fibrinolysis. Blood 2005; 106:3824–3830.[Abstract/Free Full Text] Binnie CG, Hettasch JM, Strickland E, Lord ST. Characterization of purified recombinant fibrinogen: partial phosphorylation of fibrinopeptide A. Biochemistry 1993; 32:107–113.[CrossRef][Medline] [Order article via Infotrieve] Mullin JL, Gorkun OV, Binnie CG, Lord ST. Recombinant fibrinogen studies reveal that thrombin specificity dictates order of fibrinopeptide release. J Biol Chem 2000; 275:25239–25246.[Abstract/Free Full Text] Laemmli UK. Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature 1970; 227:680–685.[CrossRef][Medline] [Order article via Infotrieve] Ariens RA, Philippou H, Nagaswami C, et al. The factor XIII V34L polymorphism accelerates thrombin activation of factor XIII and affects cross-linked fibrin structure. Blood 2000; 96:988–995.[Abstract/Free Full Text] Woodhead JL, Nagaswami C, Matsuda M, Arocha-Pinango CL, Weisel JW. The ultrastructure of fibrinogen Caracas II molecules, fibers, and clots. J Biol Chem 1996; 271:4946–4953.[Abstract/Free Full Text] Takebe M, Soe G, Kohno I, Sugo T, Matsuda M. Calcium ion-dependent monoclonal antibody against human fibrinogen: preparation, characterization, and application to fibrinogen purification. Thromb Haemost 1995; 73:662–667.[Medline] [Order article via Infotrieve] Murthy SN and Lorand L. Cross-linked A alpha. gamma chain hybrids serve as unique markers for fibrinogen polymerized by tissue transglutaminase. Proc Natl Acad Sci U S A 1990; 87:9679–9682.[Abstract/Free Full Text] Murthy SN, Wilson JH, Lukas TJ, et al. Transglutaminase-catalyzed crosslinking of the Aalpha and gamma constituent chains in fibrinogen. Proc Natl Acad Sci U S A 2000; 97:44–48.[Abstract/Free Full Text] Ryan EA, Mockros LF, Weisel JW, Lorand L. Structural origins of fibrin clot rheology. Biophys J 1999; 77:2813–2826.[Medline] [Order article via Infotrieve] Haroon ZA, Wannenburg T, Gupta M, et al. Localization of tissue transglutaminase in human carotid and coronary artery atherosclerosis: implications for plaque stability and progression. Lab Invest 2001; 81:83–93.[Medline] [Order article via Infotrieve] Weisel JW. The mechanical properties of fibrin for basic scientists and clinicians. Biophys Chem 2004; 112:267–276.[CrossRef][Medline] [Order article via Infotrieve] Scrutton MC, Ross-Murphy SB, Bennett GM, Stirling Y, Meade TW. Changes in clot deformability: a possible explanation for the epidemiological association between plasma fibrinogen concentration and myocardial infarction. Blood Coagul Fibrinolysis 1994; 5:719–723.[Medline] [Order article via Infotrieve] Fatah K, Silveira A, Tornvall P, et al. Proneness to formation of tight and rigid fibrin gel structures in men with myocardial infarction at a young age. Thromb Haemost 1996; 76:535–540.[Medline] [Order article via Infotrieve] Roska FJ and Ferry JD. Studies of fibrin film, I: stress relaxation and birefringence. Biopolymers 1982; 21:1811–1832.[CrossRef][Medline] [Order article via Infotrieve] Roska FJ, Ferry JD, Lin JS, Anderegg JW. Studies of fibrin film, II: small-angle x-ray scattering. Biopolymers 1982; 21:1833–1845.[CrossRef][Medline] [Order article via Infotrieve] Francis CW and Marder VJ. Increased resistance to plasmic degradation of fibrin with highly crosslinked alpha-polymer chains formed at high factor XIII concentrations. Blood 1988; 71:1361–1365.[Abstract/Free Full Text] Gaffney PJ and Whitaker AN. Fibrin crosslinks and lysis rates. Thromb Res 1979; 14:85–94.[CrossRef][Medline] [Order article via Infotrieve] Feddersen C and Gormsen J. Plasmin digestion of stabilized and non-stabilized fibrin illustrated by pH-stat titration and thrombelastography. Scand J Clin Lab Invest 1971; 27:175–181.[Medline] [Order article via Infotrieve] CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this? This article has been cited by other articles: E. T. O'Brien III, M. R. Falvo, D. Millard, B. Eastwood, R. M. Taylor II, and R. Superfine Ultrathin self-assembled fibrin sheets PNAS, December 9, 2008; 105(49): 19438 - 19443. [Abstract] [Full Text] [PDF] This Article Abstract Full Text (PDF) All Versions of this Article: blood-2007-01-066837v1 110/3/902    most recent Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Rights and Permissions Citing Articles Citing Articles via HighWire Citing Articles via CrossRef Citing Articles via Google Scholar Google Scholar Articles by Standeven, K. F. Articles by Ariëns, R. A. S. Search for Related Content PubMed PubMed Citation Articles by Standeven, K. F. Articles by Ariëns, R. A. S. Related Collections Hemostasis, Thrombosis, and Vascular Biology Social Bookmarking                   What's this?

	Copyright © 2007 by American Society of Hematology         Online ISSN: 1528-0020